[ad_1]
Details on the composition of the new vaccines expected soon
April 28, 2023, News Staff – The AAFP, following an expedited review, formally endorsed actions by the FDA and CDC to streamline COVID-19 vaccine recommendations for infants, children, and adults, and to enable people with increased risk of infection from receiving an additional dose of bivalent Covid-19 vaccine.
The CDC on April 19 revised its interim clinical considerations for the use of COVID-19 vaccines to include recommendations closely aligned with those of the FDA. Members of the agency’s advisory committee on immunization practices also met on April 19 and, without formally voting, expressed support for the recommendations.
The Executive Committee of the Academy’s Commission on Public Health and Science reviewed the amended EUA and revised draft clinical considerations, and submitted a recommendation for approval to the Chairman of the AAFP Board of Trustees. . The Chairman of the Board approved the recommendation on April 21.
The actions taken by the FDA and CDC are the latest in an ongoing federal effort to simplify the composition and administration of COVID-19 vaccines.
In January, the FDA’s Vaccines and Related Biologicals Advisory Committee voted unanimously to recommend “harmonizing” the composition of COVID-19 primary vaccine doses and booster doses so that all vaccines administered consist of a bivalent dose.
In February, the CDC, along with the AAFP and several other medical organizations, released the 2023 adult and child/adolescent vaccination schedules, both of which recommend routine vaccination against COVID-19 for all individuals, unless otherwise specified.
The CDCs COVID data tracker estimates that more than 104 million cases of COVID-19 have occurred in the United States since the start of the pandemic, resulting in more than 1.1 million deaths. For the week ending April 22, the Data Tracker indicates that omicron subvariants are still the variants of most concern in the United States, with one subvariant (XBB 1.5) accounting for nearly 74% of cases.
According to the FDA’s April 18 statement, the agency will discuss strain composition for COVID-19 vaccines for fall 2023 at a VRBPAC meeting in June. The date and other details will be displayed on the FDA Advisory Committee Calendar Web Page.
ACIP will hold its next meeting on June 21-22 and is expected to discuss the fall COVID-19 vaccination schedule at that time.
|
Sources 2/ https://www.aafp.org/news/health-of-the-public/simplified-covid-19-vax-recs.html The mention sources can contact us to remove/changing this article |
[ad_2]